Methimazole

is prescribed to treat:

• Hyperthyroidism and graves' disease • Various related conditions in the endocrine category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Methimazole (Tapazole) is an antithyroid drug used for hyperthyroidism, most commonly from Graves' disease, and to achieve a euthyroid state before thyroidectomy or radioiodine treatment. It is the preferred antithyroid agent in nearly all circumstances, with one specific and important exception.

Mechanism of Action

Methimazole inhibits thyroid peroxidase, the enzyme that catalyses two essential steps in thyroid hormone synthesis: iodination of tyrosine residues on thyroglobulin, and coupling of those iodinated residues to form T4 and T3.

Blocking synthesis does not affect hormone already made and stored within the thyroid follicles, and the gland holds several weeks of supply. This is why methimazole does not work immediately — clinical improvement typically begins after two to four weeks and full effect takes six to twelve. Patients told they are being treated but who feel no better for a fortnight often assume failure.

Because of that delay, a beta blocker such as metoprolol or propranolol is usually given alongside at the start, controlling the adrenergic symptoms — palpitations, tremor, anxiety, heat intolerance — within hours while the antithyroid drug works on the underlying overproduction.

Methimazole may also have mild immunosuppressive effects in Graves' disease, which is autoimmune, though how much this contributes to remission is uncertain.

Propylthiouracil is the alternative agent. It additionally blocks peripheral conversion of T4 to T3, which is useful in thyroid storm, but it carries a substantially higher risk of severe hepatotoxicity — including fatal liver failure — and it is therefore reserved for specific situations rather than used first.

Clinical Use

In Graves' disease there are three definitive options: antithyroid drugs, radioiodine, and surgery. Methimazole is the usual first choice, particularly in younger patients, in mild disease, and where remission is plausible.

Roughly a third to a half of patients achieve lasting remission after a course of twelve to eighteen months, though relapse after stopping is common — most often in the first year. Predictors of remission include mild disease, a small goitre, and low antibody titres. Patients who relapse generally proceed to radioiodine or surgery.

Methimazole is dosed once daily, an advantage over propylthiouracil's multiple daily doses, and it is more potent by weight.

Thyroid eye disease is a specific consideration in Graves', because radioiodine can worsen it while antithyroid drugs do not. In a patient with active eye involvement, methimazole is preferred and radioiodine is generally deferred or covered with corticosteroids. The thyroid checking article covers who warrants testing, and our endocrine team manages these decisions.

Agranulocytosis

The complication that governs how methimazole is prescribed is agranulocytosis — a sudden, profound loss of neutrophils leaving the patient defenceless against bacterial infection.

It is rare, occurring in well under one percent of patients, and it typically appears within the first three months, though it can occur later. It is idiosyncratic rather than dose-dependent in a predictable way, and routine blood count monitoring does not reliably catch it, because it develops faster than any practical monitoring interval.

What does work is patient education, and it must be specific. Every patient starting methimazole should be told: if you develop a fever or a sore throat, stop the drug and get a white cell count the same day. Not next week, not at the next appointment. A sore throat in a patient on methimazole is a haematological emergency until proven otherwise.

Patients frequently attribute a sore throat to an ordinary virus and wait. Framing it explicitly — including telling them to say they are taking methimazole to whoever they see — is the intervention that prevents deaths. The MedlinePlus methimazole entry covers prescribing detail, and the American Thyroid Association provides patient-level background.

Hepatotoxicity also occurs, more often cholestatic with methimazole and hepatocellular with propylthiouracil, and jaundice or dark urine warrants prompt testing.

Monitoring and Follow-Up

Thyroid function is checked every four to six weeks initially, since it takes that long for changes to express, then less frequently once stable. Free T4 and T3 guide dosing early on — TSH remains suppressed for months after the thyroid hormones normalise and is misleading if used alone at the start, which is a common source of over-treatment.

The goal is a euthyroid state, and over-treatment causing hypothyroidism is easy given the delayed feedback. Some clinicians use a block-and-replace approach, giving a fixed higher methimazole dose with levothyroxine added, though titration is more common.

Baseline complete blood count and liver enzymes are obtained. Routine serial counts are of limited value for the reason above, but a baseline distinguishes drug effect from the mild neutropenia that Graves' disease itself can cause.

Special Populations

Pregnancy is where the exception to methimazole's preference applies. Methimazole is associated with a specific pattern of congenital malformations — aplasia cutis, choanal atresia, oesophageal atresia — when used in the first trimester. Propylthiouracil is therefore preferred in the first trimester despite its hepatotoxicity, with a switch back to methimazole afterwards.

This means a woman of childbearing potential on methimazole needs contraception counselling and a plan to contact her clinician immediately on discovering pregnancy, not at the first prenatal visit. Untreated hyperthyroidism in pregnancy is itself dangerous, so stopping treatment is not the answer.

In older adults, hyperthyroidism presents atypically — atrial fibrillation, weight loss, or apathy rather than the classic hyperadrenergic picture — and cardiac complications are more likely. Both drugs pass into breast milk in small amounts and are compatible with breastfeeding at moderate doses.

When to Contact Your Doctor

Stop the drug and seek same-day assessment with a blood count for fever, sore throat, mouth ulcers, or any sign of infection. This is the single most important instruction and it should not wait for an appointment.

Report yellowing of the skin or eyes, dark urine, persistent nausea with abdominal pain, or unusual fatigue, which may indicate liver injury. Report a rash, particularly if blistering or with fever.

Report palpitations, tremor, weight loss, or heat intolerance that is not improving, and equally report fatigue, weight gain, or cold intolerance, which suggest over-treatment. Contact us immediately if you become pregnant or are planning pregnancy.

To review your thyroid levels, discuss definitive treatment options, or plan for pregnancy, contact us or schedule a visit.